Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Non-Current Deffered Revenue (2016 - 2024)

Historic Non-Current Deffered Revenue for Seres Therapeutics (MCRB) over the last 9 years, with Q2 2024 value amounting to $95.4 million.

  • Seres Therapeutics' Non-Current Deffered Revenue rose 46.04% to $95.4 million in Q2 2024 from the same period last year, while for Jun 2024 it was $95.4 million, marking a year-over-year increase of 46.04%. This contributed to the annual value of $95.4 million for FY2023, which is 317.43% up from last year.
  • Per Seres Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $95.4 million for Q2 2024, which was up 46.04% from $95.4 million recorded in Q1 2024.
  • In the past 5 years, Seres Therapeutics' Non-Current Deffered Revenue registered a high of $95.4 million during Q4 2023, and its lowest value of $78.4 million during Q2 2021.
  • In the last 5 years, Seres Therapeutics' Non-Current Deffered Revenue had a median value of $89.7 million in 2021 and averaged $88.8 million.
  • In the last 5 years, Seres Therapeutics' Non-Current Deffered Revenue plummeted by 2440.54% in 2020 and then soared by 1581.77% in 2023.
  • Over the past 5 years, Seres Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $85.6 million in 2020, then increased by 1.67% to $87.0 million in 2021, then rose by 6.24% to $92.4 million in 2022, then grew by 3.17% to $95.4 million in 2023, then changed by 0.0% to $95.4 million in 2024.
  • Its Non-Current Deffered Revenue stands at $95.4 million for Q2 2024, versus $95.4 million for Q1 2024 and $95.4 million for Q4 2023.